CRISPR Therapeutics AG

CRSP | Nasdaq | CIK: 0001674416 | SIC: 2836 Biological Products, (No Diagnostic Substances) | active
CRISPR Therapeutics AG is a biopharmaceutical company focused on developing CRISPR/Cas9-based gene editing therapeutics. Its lead product, CASGEVY (exagamglogene autotemcel), received the world's first approval of a CRISPR-based therapy in 2023 for sickle cell disease and transfusion-dependent beta thalassemia, developed in collaboration with Vertex Pharmaceuticals. The company also pursues in vivo editing, allogeneic CAR T cell therapies for autoimmune and oncology indications, and regenerative medicine programs.
hemoglobinopathies-(sickle-cell-disease,-transfusion-dependent-beta-thalassemia)oncology-(car-t-cell-therapies)autoimmune-diseases-(car-t-cell-therapies)regenerative-medicinein-vivo-gene-editing-for-common-and-rare-diseasescrispr/cas9-gene-editingex-vivo-cell-editingin-vivo-gene-editingsirnaallogeneic-car-t-cell-therapy
AI agents: Get this data as structured JSON (~200 tokens):
https://origin.rootz.global/api/company/CRSP
Profile | Timeline | SEC Filings | People

Products

NameTypeDescription
CASGEVY (exagamglogene autotemcel, exa-cel)platformFirst approved CRISPR-based therapy for sickle cell disease and transfusion-dependent beta thalassemia; approved in the US and other countries in 2023.
CTX112platformAllogeneic CAR T cell therapy candidate in development.
CTX211platformAllogeneic CAR T cell therapy candidate in development.
CTX213platformAllogeneic CAR T cell therapy candidate in clinical development.
CTX310platformIn vivo gene editing program candidate in development.
CTX321platformIn vivo gene editing program candidate in clinical development.
CTX340platformGene editing program candidate in development.
CTX460platformGene editing program candidate in development.
CTX611platformGene editing program candidate in clinical development.
zugocabtagene geleucelplatformCAR T cell therapy candidate in clinical development.

Partnerships

PartnerTypeDescription
Vertex Pharmaceuticals IncorporateddevelopmentLead collaboration on CASGEVY program; Vertex is the manufacturer and exclusive license holder of CASGEVY. Also collaborating on targeted conditioning and in vivo hematopoietic stem cell editing.

SEC Filings

View all SEC EDGAR filings: EDGAR Company Page

Structured filing index: /api/company/CRSP/filings

Origin — Data Provenance
This profile was extracted from SEC EDGAR filings (PEM-signed by sec.gov).
Every API response includes a cryptographic origin leaf for chain-of-custody tracking.
AI Discovery Document | Registry Metrics | GitHub